[go: up one dir, main page]

PE20050311A1 - 4-feniltetrahidroisoquinoleinas sustituidas, procedimiento para prepararlas, y el medicamento que las comprende - Google Patents

4-feniltetrahidroisoquinoleinas sustituidas, procedimiento para prepararlas, y el medicamento que las comprende

Info

Publication number
PE20050311A1
PE20050311A1 PE2004000261A PE2004000261A PE20050311A1 PE 20050311 A1 PE20050311 A1 PE 20050311A1 PE 2004000261 A PE2004000261 A PE 2004000261A PE 2004000261 A PE2004000261 A PE 2004000261A PE 20050311 A1 PE20050311 A1 PE 20050311A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
phenyl
tetrahydroisoquinolein
dichloro
Prior art date
Application number
PE2004000261A
Other languages
English (en)
Inventor
Armin Hofmeister
Uwe Heinelt
Hans-Jochen Lang
Wendelin Frick
Markus Bleich
Klaus Wirth
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20050311A1 publication Critical patent/PE20050311A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 4-FENILTETRAHIDROQUNOLEINAS DE FORMULA (I), DONDE R1, R2, R3 Y R4 SON INDEPENDIENTEMENTE H, F, Cl, Br, I, CN, NO2, OH, ALQUILO(C1-C8), CICLOALQUILO(C3-C8), O-ALQUILO(C1-C8), OPCIONALMENTE FLUORADOS, Ok-(CH2)-FENILO, ENTRE OTROS; R5 ES H, ALQUILO(C1-C8), CICLOALQUILO(C3-C8), COR20 O SO2R20; R6 ES H, OH, F, Cl, Br, ALQUILO(C1-C8), CICLOALQUILO(C3-C8), ENTRE OTROS; R7, R8 Y R9 SON H, F, Cl, Br, I, OH, ALQUILO(C1-C8), CICLOALQUILO (C3-C8), OPCIONALMENTE FLUORADOS; Ov-SOw-R47, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[4-(6,8-DICLORO-2-METIL-1,2,3,4-TETRAHIDROISOQUINOLEIN-4-IL)FENIL]-2,3,4,5,6-PENTAHIDROXI-HEXANAMIDA, 1-[3-(6,8-DICLORO-2-METIL-1,2,3,4-TETRAHIDROISOQUINOLEIN-4-IL)FENIL]-3-(2-HIDROXI-1-HIDROXI-METILETIL)UREA, {3-[4-(6,8-DICLORO-2-METIL-1,2,3,4-TETRAHIDROISOQUINOLEIN-4-IL)FENIL]UREIDO}ACETATO DE ETILO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DEL INTERCAMBIADOR DE SODIO-HIDROGENO (NHE), ESPECIALEMENTE EL INTERCAMBIADOR DE SODIO-HIDROGENO DEL SUBTIPO 3 (NH3) Y SON UTILES EN TRATAMIENTO DE TRANSTORNOS RENALES, COMO INSUFICIENCIA RENAL, TRANSTORNOS DE LA FUNCION BILIAR, RESPIRATORIOS Y EN EL ACCIDENTE CEREBRO VASCULAR
PE2004000261A 2003-03-24 2004-03-10 4-feniltetrahidroisoquinoleinas sustituidas, procedimiento para prepararlas, y el medicamento que las comprende PE20050311A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10312963A DE10312963A1 (de) 2003-03-24 2003-03-24 Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
PE20050311A1 true PE20050311A1 (es) 2005-06-06

Family

ID=32946086

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000261A PE20050311A1 (es) 2003-03-24 2004-03-10 4-feniltetrahidroisoquinoleinas sustituidas, procedimiento para prepararlas, y el medicamento que las comprende

Country Status (22)

Country Link
EP (1) EP1613600B1 (es)
JP (1) JP2006521306A (es)
KR (1) KR20050115304A (es)
CN (1) CN100364978C (es)
AR (1) AR043741A1 (es)
AU (1) AU2004224242B2 (es)
BR (1) BRPI0408744A (es)
CA (1) CA2519658A1 (es)
DE (1) DE10312963A1 (es)
HR (1) HRP20050843A2 (es)
MA (1) MA27751A1 (es)
ME (1) MEP42908A (es)
MX (1) MXPA05010003A (es)
MY (1) MY139498A (es)
NO (1) NO20054876L (es)
NZ (1) NZ542608A (es)
PE (1) PE20050311A1 (es)
RS (1) RS20050713A (es)
RU (1) RU2343147C2 (es)
TW (1) TW200510321A (es)
WO (1) WO2004085404A1 (es)
ZA (1) ZA200506422B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004046492A1 (de) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102006012544A1 (de) 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 1-Amino 4-phenyl-dihydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
BRPI0714315B8 (pt) * 2006-06-29 2021-05-25 Hoffmann La Roche arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
JPWO2008004610A1 (ja) * 2006-07-05 2009-12-03 国立大学法人 東京大学 ナンセンス変異型遺伝性疾患の治療方法
WO2009141782A1 (en) * 2008-05-19 2009-11-26 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolines as antimalarial agents
JP5502106B2 (ja) * 2008-12-31 2014-05-28 アーデリクス，インコーポレーテッド 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるｎｈｅ媒介性アンチポートを阻害するための組成物および方法
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ME02908B (me) * 2011-08-25 2018-10-20 Medicines For Malaria Venture Mmv Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije
KR102287207B1 (ko) * 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
RU2538085C2 (ru) * 2013-05-08 2015-01-10 Любовь Демьяновна Шаманская Препарат для борьбы с экзопаразитами животных
BR112017000691B1 (pt) 2014-07-25 2023-02-14 Taisho Pharmaceutical Co., Ltd Feniltetra-hidroisoquinolina substituído com heteroari-la, seu uso, medicamento, inibidores de nhe3, de absorção de sódio e de absorção de fósforo, promotor de secre-ção de água intestinal e fármaco profilático ou terapêu-tico para constipação
CA3049679A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
UA126283C2 (uk) 2017-01-09 2022-09-14 Арделікс, Інк. Сполуки, придатні для лікування розладів шлунково-кишкового тракту
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
ES2927100T3 (es) * 2019-05-16 2022-11-02 Lilly Co Eli Compuestos inhibidores del intercambiador de sodio-hidrógeno 3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
JPH06256311A (ja) * 1993-02-26 1994-09-13 Nippon Shinyaku Co Ltd イソキノリノール誘導体及び医薬
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
SE9600769D0 (sv) * 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
KR20080065707A (ko) * 1999-11-03 2008-07-14 에이엠알 테크놀로지, 인크. 4-페닐-치환 테트라히드로이소퀴놀린, 및 노르에피네프린과도파민과 세로토닌의 재흡수를 차단하기 위한 이의 용도
ATE387429T1 (de) * 1999-11-03 2008-03-15 Amr Technology Inc Arly- und heteroaryl-substituierte tetrahydroisoquinoline und ihre verwendung als hemmer der wiederaufnahme von norepinephrin, dopamin und serotonin
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
NZ533322A (en) * 2001-12-05 2006-02-24 Sanofi Aventis Deutschland Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10163992A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline

Also Published As

Publication number Publication date
HRP20050843A2 (en) 2006-09-30
RU2343147C2 (ru) 2009-01-10
HK1090042A1 (en) 2006-12-15
CA2519658A1 (en) 2004-10-07
JP2006521306A (ja) 2006-09-21
NO20054876D0 (no) 2005-10-21
AU2004224242A1 (en) 2004-10-07
NZ542608A (en) 2009-07-31
NO20054876L (no) 2005-12-06
MEP42908A (en) 2011-02-10
WO2004085404A1 (de) 2004-10-07
MXPA05010003A (es) 2005-11-17
AR043741A1 (es) 2005-08-10
RU2006127170A (ru) 2008-02-10
DE10312963A1 (de) 2004-10-07
RS20050713A (sr) 2007-11-15
BRPI0408744A (pt) 2006-04-18
CN1798737A (zh) 2006-07-05
KR20050115304A (ko) 2005-12-07
EP1613600B1 (de) 2015-12-23
EP1613600A1 (de) 2006-01-11
ZA200506422B (en) 2007-02-28
CN100364978C (zh) 2008-01-30
AU2004224242B2 (en) 2010-03-18
MY139498A (en) 2009-10-30
MA27751A1 (fr) 2006-02-01
TW200510321A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
PE20050311A1 (es) 4-feniltetrahidroisoquinoleinas sustituidas, procedimiento para prepararlas, y el medicamento que las comprende
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR055165A1 (es) Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c.
PE20050354A1 (es) Aminas ciclicas de bace-1 que poseen un sustituyente heterociclico
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
RU2007143073A (ru) Азольные соединения с нейтротерапевтической активностью
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR049124A1 (es) Compuestos de de pirimidinona como inhibidores de la integrasa del virus hiv, composiciones farmaceuticas que las contienen y su uso en el tratamiento del sida y de la infeccion por hiv
BRPI0516063A (pt) sìntese de n-(4-fluorbenzil)-n-(1-metilpiperidin-4-il)-n'-(4-(2-metilp ropi-loxi)fenilmetil)carbamida e seu sal tartarato e formas cristalinas
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
PE20090509A1 (es) El uso de derivados de benzamida para el tratamiento de transtornos del snc
PE20070751A1 (es) Derivados de isoxazolidina como inhibidores de la interaccion de proteinas bcl
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
AR076460A1 (es) Antagonistas del receptor cxcr3
MX2010001080A (es) Pirrolidin-aril-eteres como antagonistas de receptor de nk3.
PE20080429A1 (es) Analogos de piperidina, morfolina y pirrolidinilo
PE20091823A1 (es) Ciclohexildiaminas sustituidas
RU2009122666A (ru) Производные гетероарилпирролидинил- и пиперидинилкетона
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
PE20050460A1 (es) COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed